Systemic treatment strategies for triple-negative breast cancer

Table 2 Chemotherapy regimen with their outcomes in triple-negative breast cancer

Ref.	Yr	No.	Therapy	Outcome
Martin et al[12]	2010	171	FEC FEC + P	7 yr DFS 56% vs 74%
Byrski et al[23]	2009	25	Cisplatin + P + GSF	5 yr DFS-76% DDFS-84%
Koshy et al[32]	2010	17	Cisplatin + gemcitabine	PFS-5.3 mo TNBC vs 1.7 mo non-TNBC
Maisano et al[31]	2011	31	Carboplatin + gemcitabine	ORR-32% PFS-5.5 mo

Anthracyclin and taxane pretreated TNBC patients. GSF: Granulocyte stimulating factor; ORR: Overall response rate; PFS: Progression free survival; DFS: Disease free survival; DDFS: Distant disease free survival; TNBC: Triple-negative breast cancer; P: Paclitaxel; FEC: 5-Fluorouracil, epirubicin, cyclophosphamide.